144 related articles for article (PubMed ID: 34148911)
1. Safety of alternate-day treatment with TS-1
Nishiyama Y; Fukuyama Y; Maruo T; Yoda S; Iwano M; Kawarai S; Kayanuma H; Orito K
J Vet Med Sci; 2021 Aug; 83(8):1206-1211. PubMed ID: 34148911
[TBL] [Abstract][Full Text] [Related]
2. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.
Wang HF; Lv JQ
Cell Biochem Biophys; 2015 Jul; 72(3):695-9. PubMed ID: 25618173
[TBL] [Abstract][Full Text] [Related]
4. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
5. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Kim TH; Shin S; Shin JC; Bulitta JB; Weon KY; Yoo SD; Park GY; Jeong SW; Kwon DR; Min BS; Woo MH; Shin BS
Molecules; 2017 Sep; 22(9):. PubMed ID: 28880240
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
Wang T; Zhang SF; Qiu MQ; Li QL
Cancer Radiother; 2016 May; 20(3):181-6. PubMed ID: 27068497
[TBL] [Abstract][Full Text] [Related]
8. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Tsuda A; Fujiyama J; Miki A; Hori S; Ohtani H; Sawada Y
Cancer Chemother Pharmacol; 2008 Aug; 62(3):427-32. PubMed ID: 18026730
[TBL] [Abstract][Full Text] [Related]
9. [Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
Duh D; Warnez M
J Pharm Belg; 2013 Dec; (4):35-6. PubMed ID: 24449972
[No Abstract] [Full Text] [Related]
10. Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
Komatsu-Fujii T; Ogawa M; Nonoyama S; Fukumoto T; Tanabe H
Eur J Dermatol; 2021 Feb; 31(1):98-99. PubMed ID: 33586655
[No Abstract] [Full Text] [Related]
11. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
12. Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Matsuda K; Namiki T; Ueno M; Hashimoto T; Hanafusa T; Yokozeki H
Eur J Dermatol; 2017 Jun; 27(3):323-325. PubMed ID: 28414195
[No Abstract] [Full Text] [Related]
13. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
14. Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancer.
Meng C; Lu Z; Fang M; Zhou X; Dai K; Zhang S; Luo J; Luo Z
Int J Clin Exp Pathol; 2014; 7(11):7622-32. PubMed ID: 25550798
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Lee HW; Seong SJ; Kang WY; Ohk B; Gwon MR; Kim BK; Cho S; Cho K; Sung YK; Yoon YR; Kim JG
Drug Des Devel Ther; 2019; 13():3127-3136. PubMed ID: 31564829
[TBL] [Abstract][Full Text] [Related]
17. Eccrine squamous syringometaplasia of underlying syringoma associated with Tegafur/Gimeracil/Oteracil (TS-1).
Kim J; Kim SH; Lee MG; Chung KY; Kim DS
Acta Derm Venereol; 2015 Nov; 95(8):999-1000. PubMed ID: 25766447
[No Abstract] [Full Text] [Related]
18. Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study.
Ishizuna K; Ninomiya J; Ogawa T; Kojima M; Tsuji E; Kawashima M; Nozaki M; Yamagishi H; Ueda Y
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2577-82. PubMed ID: 25596051
[TBL] [Abstract][Full Text] [Related]
19. Acral lentiginosis associated with tegafur/gimeracil/oteracil (TS-1).
Park YJ; Soh BW; Lee ES
Eur J Dermatol; 2017 Apr; 27(2):209-210. PubMed ID: 28251899
[No Abstract] [Full Text] [Related]
20. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
Chollet P; Schöffski P; Weigang-Köhler K; Schellens JH; Cure H; Pavlidis N; Grünwald V; De Boer R; Wanders J; Fumoleau P;
Eur J Cancer; 2003 Jun; 39(9):1264-70. PubMed ID: 12763215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
